Short Interest in ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) Rises By 1,291.0%

ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) saw a significant growth in short interest in the month of January. As of January 15th, there was short interest totalling 276,800 shares, a growth of 1,291.0% from the December 31st total of 19,900 shares. Currently, 11.8% of the shares of the stock are sold short. Based on an average trading volume of 1,850,000 shares, the days-to-cover ratio is presently 0.1 days.

ZyVersa Therapeutics Stock Up 0.7 %

ZVSA stock opened at $1.38 on Friday. The firm’s fifty day moving average is $1.20 and its 200 day moving average is $2.09. ZyVersa Therapeutics has a 52 week low of $0.98 and a 52 week high of $25.00.

ZyVersa Therapeutics Company Profile

ZyVersa Therapeutics, Inc, a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. The company develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial to the treatment of renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney diseases; and Inflammasome ASC Inhibitor IC 100, a humanized monoclonal antibody that is in preclinical stage for treatment of inflammatory diseases comprising acute respiratory syndrome, multiple sclerosis, IgA neuropathy, pancreatic cancer, Parkinson's and Huntington's disease, atherosclerosis, Alzheimer's disease, and obesity.